Increased levels of interleukins 8 and 10 as findings of canine inflammatory mammary cancer.
Inflammatory mammary cancer (IMC) is a distinct form of mammary cancer that affects dogs and women [in humans, IMC is known as inflammatory breast cancer (IBC)], and is characterized by a sudden onset and an aggressive clinical course. Spontaneous canine IMC shares epidemiologic, histopathological and clinical characteristics with the disease in humans and has been proposed as the best spontaneous animal model for studying IBC, although several aspects remain unstudied. Interleukins (ILs) play an important role in cancer as potential modulators of angiogenesis, leukocyte infiltration and tumor growth. The aims of the present study were to assess serum and tumor levels of several ILs (IL-1α, IL-1β, IL-6, IL-8 and IL-10) by enzyme-immunoassay in dogs bearing benign and malignant mammary tumors, including dogs with IMC, for a better understanding of this disease. Forty-eight dogs were prospectively included. Animals consisted of 7 healthy Beagles used as donors for normal mammary glands (NMG) and serum controls (SCs), 10 dogs with hyperplasias and benign mammary tumors (HBMT), 24 with non-inflammatory malignant mammary tumors (non-IMC MMT) and 7 dogs with clinical and pathological IMC. IL-8 (serum) and IL-10 (serum and tissue homogenate) levels were higher in the dogs with IMC compared with the non-IMC MMT group. ILs were increased with tumor malignancy as follows: in tumor homogenates IL-6 levels were higher in malignant tumors (IMC and non-IMC MMT) versus HBMT and versus NMG and tumor IL-8 was increased in malignant tumors versus NMG; in serum, IL-1α and IL-8 levels were higher in the malignant groups respect to HBMT and SCs; interestingly, IL-10 was elevated only in the serum of IMC animals. To the best of our knowledge, this is the first report that analyzes ILs in IMC and IL-10 in canine mammary tumors. Our results indicate a role for IL-6, IL-8 and IL-10 in canine mammary malignancy and specific differences in ILs content in IMC versus non-IMC MMT that could have future diagnostic and therapeutic implications, to be confirmed in a larger series of IMC cases. These results help to support the validity of the IMC canine model for the study of human IBC and provide insight into this uncommon malignancy in dogs.
Dept. Medicina y Cirugía Animal. Facultad de Veterinaria, Avda/Puerta de Hierro s/n, Universidad Complutense de Madrid, Spain. pjdeandres@hotmail.com
Paloma Jimena
PJ
de Andrés
Juan Carlos
JC
Illera
Sara
S
Cáceres
Lucía
L
Díez
Maria Dolores
MD
Pérez-Alenza
Laura
L
Peña
D000818:Animals; D014408:Biomarkers, Tumor / Q000097:blood* / Q000378:metabolism; D016022:Case-Control Studies; D004283:Dog Diseases / Q000276:immunology* / Q000473:pathology; D004285:Dogs; D005260:Female; D006801:Humans; D058922:Inflammatory Breast Neoplasms / Q000276:immunology; D016753:Interleukin-10 / Q000097:blood* / Q000378:metabolism; D016209:Interleukin-8 / Q000097:blood* / Q000378:metabolism; D007378:Interleukins / Q000097:blood / Q000378:metabolism; D008321:Mammary Glands, Animal / Q000276:immunology; D015674:Mammary Neoplasms, Animal / Q000276:immunology* / Q000473:pathology; D013045:Species Specificity
D014408:Biomarkers, Tumor; D016209:Interleukin-8; D007378:Interleukins; D016753:Interleukin-10